Home
Who We Are
Who We Are
Testimonials
Collaborations
Consulting
Inspection Readiness
GxP Auditing
Quality Systems
Quality Risk Management
Monitoring Services
Training
GCP Training Services
Training Courses
DIGR-ACT
DIGR-ACT - Home
DIGR-ACT - About
DIGR-ACT - Contact Us
Online Store
Catalog
Blog
Contact

Clinical Pathways

Home
Who We Are
Who We Are
Testimonials
Collaborations
Consulting
Inspection Readiness
GxP Auditing
Quality Systems
Quality Risk Management
Monitoring Services
Training
GCP Training Services
Training Courses
DIGR-ACT
DIGR-ACT - Home
DIGR-ACT - About
DIGR-ACT - Contact Us
Online Store
Catalog
Blog
Contact
June 3, 2025
Guest User
Final Guidance Released on IRB Written ...

06/03/2025

-

In February 2025, the US Food and Drug Administration (FDA) and the Department of Health and Human Services (HHS) Office for Human Research Protection (OHRP) released the final guidance “Institutional Review Board (IRB) Written Procedures.”

Final Guidance Released on IRB Written Procedures
May 30, 2025
Guest User
Now Available: Clinical Pathways’ Major Changes ...

05/30/2025

-

In the ever changing world of clinical research, staying up to date with the latest guidelines and best practices is crucial. Our Major Changes in GCP from ICH E6(R2) to (R3): Road Map is designed for busy professionals who want to deepen their knowledge on GCP to help ensure they meet the highest standards of quality, safety, and compliance.

May 21, 2025
Guest User
FDA Draft Guidance on Considerations for AI Use

05/21/2025

-

In January 2025, the US Food and Drug Administration (FDA) published a draft guidance titled “Considerations for the Use of Artificial Intelligence (AI) to Support Regulatory Decision-Making for Drug and Biological Products” for trial sponsors and stakeholders intending to use AI to generate data and clinical evidence.

FDA Draft Guidance on Considerations for AI Use
April 30, 2025
Guest User
EMA on the use of Real-World Data/Evidence in ...

04/30/2025

-

In March, 2025, the European Medicines Agency (EMA) released a “Reflection paper on use of real-world data (RWD) in non-interventional studies (NIS) to generate real-world evidence (RWE) for regulatory purposes” as a guidance for stakeholders on quality planning, conduct and analysis of NISs that intend to use RWD to generate RWE.

EMA on the use of Real-World Data/Evidence in Non-Interventional Studies
April 22, 2025
Guest User
FDA Warning Letter to Sponsor – Records, ...

04/22/2025

-

In November 2024, the US Food and Drug Administration (FDA) issued a warning letter to the sponsor as a result of a BioResearch Monitoring Program (BIMO) inspection which observed objectionable conditions. The warning letter cited two violations of the Title 21 CFR.

FDA Warning Letter to Sponsor – Records, Reports, and Audit Trails
Sandra Sather
December 9, 2014

Just Released: OHRP 2015 Edition of the International Compilation of Human Research Standards

Sandra Sather
December 9, 2014

12/09/2014

The OHRP 2015 edition of the International Compilation of Human Research Standards has just been released. View it here and learn more on what was discussed!

Sandra Sather
December 9, 2014

RBM Workshop live: Less than Two Weeks Away!

Sandra Sather
December 9, 2014

12/09/2014

I will be presenting a 1/2 day workshop. Ring in the New Year!

Sandra Sather
November 16, 2014

New Draft Guidance from OHRP: Disclosing Reasonably Foreseeable Risks in Research Evaluating Standards of Care

Sandra Sather
November 16, 2014

11/16/2014

On October 20th, the Office for Human Research Protections’ (OHRP’s) released a new draft guidance which when finalized, will represent their current thinking on this topic.

Sandra Sather
October 13, 2014

Follow-up: Site Solution Summit Master Workshops and Conference

Sandra Sather
October 13, 2014

10/13/14

The Site Solution Summit was another example of great collaborations increasing between Sites, IRBs, Sponsors and CROs!  We are in an exciting era for clinical trials. Like we heard in the FDA presentation, clinical "trails".  

Sandra Sather
September 22, 2014

CRA Oversight

Sandra Sather
September 22, 2014

09/22/2014

Using a “risk-based” approach has paid big dividends in clinical trials, as its principles are applicable to many different functional areas. This is no more visible than when applied to the oversight of Clinical Research Associates (CRA).

Older Posts
 
Archive List
  • 2013 6
  • 2014 31
  • 2015 25
  • 2016 21
  • 2017 31
  • 2018 55
  • 2019 56
  • 2020 63
  • 2021 50
  • 2022 39
  • 2023 27
  • 2024 25
  • 2025 17

Subscribe to Blogs and Newsletters.

By signing up, you agree to our our Privacy Policy. You may unsubscribe from emails at any time.

Thank you! You will receive a confirmation email shortly.

Back to Top
Clinical Pathwaysinfo@clinicalpathwaysresearch.com

Cookie Notice | License Agreement | Privacy Policy | Return Policy | Terms and Conditions | Data Security Policy | Confidentiality Policy

© 2025 Clinical Pathways. All rights reserved.